N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Olivia Dean, Frank Giorlando, Michael Berk

Mental Health Research Institute, Parkville, Victoria, Australia.

Journal Article: Journal of psychiatry & neuroscience: JPN (impact factor: 3.58). 03/2011; 36(2):78-86. DOI: 10.1503/jpn.100057

Abstract

There is an expanding field of research investigating the benefits of alternatives to current pharmacological therapies in psychiatry. N-acetylcysteine (NAC) is emerging as a useful agent in the treatment of psychiatric disorders. Like many therapies, the clinical origins of NAC are far removed from its current use in psychiatry. Whereas the mechanisms of NAC are only beginning to be understood, it is likely that NAC is exerting benefits beyond being a precursor to the antioxidant, glutathione, modulating glutamatergic, neurotropic and inflammatory pathways. This review outlines the current literature regarding the use of NAC in disorders including addiction, compulsive and grooming disorders, schizophrenia and bipolar disorder. N-acetylcysteine has shown promising results in populations with these disorders, including those in whom treatment efficacy has previously been limited. The therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

acetylated amino acid
 
addiction
 
alternatives
 
antioxidant
 
clinical origins
 
current literature
 
current pharmacological therapies
 
current use
 
disorders
 
expanding field
 
grooming disorders
 
inflammatory pathways
 
modulating glutamatergic
 
N-acetylcysteine
 
NAC
 
promising results
 
psychiatric disorders
 
schizophrenia
 
therapeutic potential
 
useful agent